Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd
Summary
This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.
Official title: A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4712 in Patients With Advanced Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
15
Start Date
2025-06-09
Completion Date
2027-05
Last Updated
2026-01-28
Healthy Volunteers
No
Conditions
Interventions
SHR-4712 Injection
SHR-4712 injection.
Locations (2)
Fujian Cancer Hospital
Fuzhou, Fujian, China
Hunan Cancer Hospital
Changsha, Hunan, China